BioAtla reports Q2 2023 net loss of $35.8M; cash $168.7M funds into 2025

BioAtla, Inc.

2023-Q2 EPS reported -$1.33

Net loss of $35.8M for Q2 2023 vs $28.9M in Q2 2022; R&D expenses rose to $31.0M from $20.7M.
Cash at June 30, 2023 was $168.7M, down from $215.5M at Dec 31, 2022; expected to fund operations into 2025.
Phase 2 potentially registrational BA3011 UPS study continues enrolling; FDA meeting request submitted for NSCLC study.
CAB-CTLA-4 BA3071 cleared fifth cohort (5 mg/kg) with no DLTs; sixth cohort enrolling; Phase 1 data readout on track for 2H23.
Anticipated data across BA3021 NSCLC, melanoma, SCCHN to enable 'go' decision for indications in 2H23.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BioAtla, Inc. reported the quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the sa.

Period: the quarter ended June 30, 2023
Net income: Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the sa
Result: reported results

Exact text from the filing

Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the same quarter in 2022.

View on SEC.gov

Browse all earnings releases →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-036440

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.